Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
3 Articles
3 Articles
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore - Life Sciences British Columbia
Exclusive collaboration and licensing agreement for povetacicept in the region – Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved – BOSTON & SHANGHAI & CAMBRIDGE, MA – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) announced an exclusive collaboration and license agr…
— Exclusive cooperation and licensing agreement on povetacicept in relevant regions — Rethinking Pharmaceuticals will leverage its local expertise and commercialization to accelerate the development of povetacicept and bring the product to patients suitable for relevant regions after approval in Boston, Shanghai, China, and Cambridge, Massachusetts, USA by 2025 1 10/US News/— Redding Pharmaceuticals (Nasdaq Stock Code: ZLAB; HKEx Stock Code: 968…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
